The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aims: The duodenal‐jejunal bypass sleeve (( DJBS ) or EndoBarrier G astrointestinal Liner) induces weight loss in obese subjects and may improve glucose homeostasis in patients with type 2 diabetes ( T2D ). To explore the underlying mechanisms, we evaluated postprandial physiology including glucose metabolism, gut hormone secretion, gallbladder emptying, appetite and food intake in patients undergoing DJBS treatment. Material and methods: A total of 10 normal glucose‐tolerant ( NGT ) obese subjects and 9 age‐, body weight‐ and body mass index‐matched metformin‐treated T2D patients underwent a liquid mixed meal test and a subsequent ad libitum meal test before implantation with DJBS and 1 week (1w) and 26 weeks (26w) after implantation. Results: At 26w, both groups had achieved a weight loss of 6 to 7 kg. Postprandial glucagon‐like peptide‐1 ( GLP ‐1) and peptide YY responses increased at 1w and 26w, but only in T2D subjects. In contrast, glucose‐dependent insulinotropic polypeptide responses were reduced only by DJBS in the NGT group. Postprandial glucose, insulin, C‐peptide, glucagon, cholecystokinin and gastrin responses were unaffected by DJBS in both groups. Satiety and fullness sensations were stronger and food intake was reduced at 1w in NGT subjects; no changes in appetite measures or food intake were observed in the T2D group. No effect of DJBS on postprandial gallbladder emptying was observed, and gastric emptying was not delayed. Conclusions: DJBS ‐induced weight loss was associated with only marginal changes in postprandial physiology, which may explain the absence of effect on postprandial glucose metabolism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sjöström, L. (2013) · Journal of Internal Medicine · doi:10.1111/joim.12012 · Cited by 1,835
Chang, S.-H., Stoll, C. R. T., Song, J., Varela, J. E., Eagon, C. J., & Colditz, G. A. (2014) · JAMA Surgery · doi:10.1001/jamasurg.2013.3654 · Cited by 1,688
Inhibition of Food Intake in Obese Subjects by Peptide YY 3–36
Batterham, R. L., Cohen, M. A., Ellis, S. M., Le Roux, C. W., Withers, D. J., Frost, G. S., Ghatei, M. A., & Bloom, S. R. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030204 · Cited by 1,604 · cited 3×
“8) kg/m(2); glycated hemoglobin A1c (HbA1c), 32 [25-43] mmol/mol; fasting plasma glucose [FPG], 5.”
BackgroundEnergy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men.
Näslund, E., Barkeling, B., King, N., Gutniak, M., Blundell, J., Holst, J., Rössner, S., & Hellström, P. (1999) · International Journal of Obesity · doi:10.1038/sj.ijo.0800818 · Cited by 468 · cited 4×
“8) kg/m(2); glycated hemoglobin A1c (HbA1c), 32 [25-43] mmol/mol; fasting plasma glucose [FPG], 5.”
BackgroundInfluentialSelf-citationFlint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 4×
“8) kg/m(2); glycated hemoglobin A1c (HbA1c), 32 [25-43] mmol/mol; fasting plasma glucose [FPG], 5.”
BackgroundInfluentialSelf-citationJørgensen, N. B., Jacobsen, S. H., Dirksen, C., Bojsen-Møller, K. N., Naver, L., Hvolris, L., Clausen, T. R., Wulff, B. S., Worm, D., Lindqvist Hansen, D., et al. (2012) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00073.2012 · Cited by 313
Cited by
Long term outcomes of metabolic/bariatric surgery in adults
Courcoulas, A. P., Daigle, C. R., & Arterburn, D. E. (2023) · BMJ · doi:10.1136/bmj-2022-071027 · Cited by 164
Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents
Gasbjerg, L. S., Gabe, M. B. N., Hartmann, B., Christensen, M. B., Knop, F. K., Holst, J. J., & Rosenkilde, M. M. (2018) · Peptides · doi:10.1016/j.peptides.2017.11.021 · Cited by 85
Endoscopic bariatrics: current therapies and future directions
Reja, D., Zhang, C., & Sarkar, A. (2022) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2020.03.09 · Cited by 24
Roehlen, N., Laubner, K., Nicolaus, L., Schwacha, H., Bettinger, D., Krebs, A., Thimme, R., & Seufert, J. (2022) · Nutrition · doi:10.1016/j.nut.2022.111806 · Cited by 17
Ren, M., Zhou, X., Lv, L., & Ji, F. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00448 · Cited by 12
Metadata
- Authors
- Rohde, U., Federspiel, C. A., Vilmann, P., Langholz, E., Friis, S. U., Krakauer, M., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2016-11-14
- Volume
- 19
- Issue
- 2
- Pages
- 189-199
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2529729908
- Cited by
- 30
- References
- 6
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes. https://app.cochat.ai/papers/10.1111/dom.12800
- The paper
- Rohde, U., Federspiel, C. A., Vilmann, P., Langholz, E., Friis, S. U., Krakauer, M., Rehfeld, J. F., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2017). The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12800
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.